{
    "clinical_study": {
        "@rank": "50484", 
        "brief_summary": {
            "textblock": "To examine the continued safety and tolerability of four doses of vesnarinone in\n      HIV-infected patients who have completed a short-term study (less than 12 months on\n      continuous treatment) of the drug."
        }, 
        "brief_title": "A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients who have completed a limited duration study (less than 12 months of continuous\n      treatment) of vesnarinone on protocols FDA 234A or FDA 234B and who have no current signs or\n      symptoms of AIDS-defining illnesses may roll over to this study and continue receiving their\n      regimen of vesnarinone for 12 months beyond their original participation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Chemoprophylaxis for Pneumocystis carinii, candida, and mycobacteria.\n\n          -  Acyclovir for acute treatment of herpes.\n\n        Exclusion Criteria\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Antiretroviral agents, including ddI, ddC, AZT, and d4T.\n\n          -  Immunosuppressive agents.\n\n          -  Investigational HIV drugs/therapies including vaccines.\n\n          -  Interferon or other immunomodulating agents.\n\n          -  Corticosteroids (other than topical).\n\n          -  Megestrol acetate.\n\n          -  Agents known to cause neutropenia.\n\n          -  Ganciclovir.\n\n          -  Cytotoxic chemotherapy.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Radiation therapy.\n\n        Patients with the following prior conditions are excluded:\n\n          -  Poor compliance (less than 80 percent of drug taken) on the Phase I protocol (FDA\n             234A or FDA 234B).\n\n          -  Missed more than one clinic visit on the Phase I protocol.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Acyclovir as prophylaxis for herpes within 48 hours prior to study entry.\n\n        Patients meet the following criteria:\n\n        Successful completion of short-term therapy with vesnarinone on FDA 234A or FDA 234B.\n\n        Active illicit drug abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002130", 
            "org_study_id": "234C", 
            "secondary_id": "22-93-253"
        }, 
        "intervention": {
            "intervention_name": "Vesnarinone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Vesnarinone"
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "Antiviral Agents", 
            "vesnarinone"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "900121973"
                    }, 
                    "name": "UCLA School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "AIDS Research Consortium of Atlanta"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002130"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Otsuka America Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1996"
    }, 
    "geocoordinates": {
        "AIDS Research Consortium of Atlanta": "33.749 -84.388", 
        "UCLA School of Medicine": "34.052 -118.244"
    }
}